MiR-182 inhibits proliferation, migration, invasion and inflammation of endometrial stromal cells through deactivation of NF-B signaling pathway in endometriosis
Pore-forming activity and structural autoinhibition of the gasdermin family
Common capsule dosages: 250 mcg to 500 mcg per capsule
Tirzepatide causes gastrointestinal symptoms including nausea, vomiting, diarrhea, and constipation in a substantial percentage of users, particularly during dose escalation phases
-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Once a multi-dose vial has been punctured for the first use, it is generally recommended to discard any remaining solution after approximately 28 days for sterility reasons, even if this falls within the original beyond-use date